Метаболический синдром и кардиоваскулярные нарушения при подагре
Диссертация
Впервые изучен метаболический синдром у больных подагрой и его влияние на развитие и течение болезни. Помимо уточнения широкой распространенности как полного метаболического синдрома, так и его отдельных симптомокомплексов, был продемонстрирован его вклад в развитие подагры. Показано, что наличие ожирения и артериальной гипертензии, развивающихся в молодом возрасте, обуславливает раннее начало… Читать ещё >
Список литературы
- Барскова В.Г., Якунина И. А., Насонова В. А. Применение нимесила при подагрическом артрите // Тер архив.- 2003. — № 5.- С. 60−64.
- Гудцент Ф. (Gudzent F.) Подагра и ревматизм.- Пер. с нем.- M.-JI. -1931.
- Джанашия П.Х., Диденко В. А. Является ли гиперурикемия компонентом метаболического синдрома//Росс, кардиол. журнал.- 2001.- № 1.- С. 28−34.
- Зимин Ю.В. Инсулинорезистентность, гиперинсулинемия и артериальная гипертония // Кардиология.- 1996.-№ 11.- С. 80−89.
- Карпов Ю.А., Сорокин Е. В. Стабильная ишемическая болезнь сердца: стратегия и тактика лечения.- Реафарм: Москва, 2003.- С. 7−16.
- Ланг Г. Ф. Гипертоническая болезнь.- Москва, 1950.
- Мадянов И.В., Балаболкин М. И., Григорьев А. А. и др. Гиперурикемия как составляющая метаболического синдрома X // Пробл. эндокринологии.- 1997.-№ 6.- С. 30−32.
- Мамедов М.Н., Перова Н. В., Метельская В. А., Оганов Р. Г. Связь абдоминального типа ожирения и синдрома инсулинорезистентности у больных артериальной гипертонией / Кардиология.- 1999.-№ 9.- С. 18−22.
- Мясников А.Л. Атеросклероз. — Москва, 1960.
- Ю.Насонов Е. Л. Маркеры воспаления и атеросклероз: значение С-реактивного белка // Кардиология.- 1999.- № 2.- С. 81−85.
- П.Насонов Е. Л. Иммунологические маркеры атеросклероза // Тер. архив.-2002, — № 5.- С. 80−85.
- Насонова В.А., Барскова В. Г. Ранние диагностика и лечение подагры — научно обоснованное требование улучшения трудового и жизненного прогноза больных // Научно-практическая ревматология. -2004.-№ 1.- С. 5−7.
- Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA.- Медиа Сфера: Москва, 2003.- 312 с.
- Рябов С. И. Болезни почек.-Медицина: Москва, 1982.- 250 с.
- Тареев Е.М. Внутренние болезни. Москва, 1956.
- Тареев Е.М. Гипертоническая болезнь.- Москва, 1948.
- Якунина И.А., Барскова В. Г., Лапкина Н. А., Абайтова Н. Е., Баранов А. А. Динамика уровня С-реактивного белка при подагрическом артрите // Научно-практическая ревматология.- 2005.- № 4.- С. 38−41.
- Abate N, Garg A, Peschock RM et al. Relationship of generalized and regional adiposity to insulin sensitivity in men // J Clin Invest.- 1995.- № 96.- p. 88−98.
- Abate N. Insulin resistance and obesity: The role of fat distribution pattern // Diabetes Care.- 1996.- № 19.- p. 292−294.
- Abbott K.C., Kimmel P.L., Dharnidharka V., et al. New-onset gout after kidney transplantation: incidence, risk factors and implications // Transplantation.-2005.- № 80 (10).- p. 1383−91.
- Adams P.F., Hendershot G.E., Marano M.A. Current estimates from the National Health Interview Survey, 1996.- Vital Health Stat 10.- 1999.- 200p.
- Adrogue H.J. Glucose homeostasis and the kidney // Kidney Int.- 1992.- № 42.-p. 1266.
- Ahn K.J., Kim Y.S., Lee H.C., Park K., Huh K.B. Cyclosporine-induced hyperuricemia after renal transplant: clinical characteristics and mechanisms // Transplant Proc.- 1992.-№ 24.-p. 1391−2.
- Albert M.A., Danielson E., Rifai N., et al. Effects of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study // JAMA.- 2001.- № 28.- p. 64−70.
- Alcazar J., Ruilope L., Ladron de Guevara P. Hiperuricemia et hypertension arterial essencial //Nefrologia.- 1982.-№ 2.- p. 145−149.
- Alderman M.H. Serum uric acid as a cardiovascular risk factor for heart disease // Current Hypertension Reports.- 2001.- № 3.- p. 184−189.
- Alper A.B. Jr, Chen W., Yau L., Srinivasan S.R., Berenson G.S., Hamm L.L. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study // Hypertension. -2005.- № 45.- p. 34−38.
- American Heart Association. 2002 Heart and stroke statistical update.- Dallas, Texas: American Heart Association, 2001.
- Aronoff A. Acute gouty arthritis precipitated by chlorotiazide // N Engl J Med.- I960.- № 262.- p. 767−769.
- Arromdee E., Michet C.J., Crowson C.S. et al. Epidemiology of Gout: Is the Incidence Rising? //J Rheumatol.- 2002.- № 29.- p. 2403−6.
- Assman G., Cullen P., Schulte H. The Munster heart study (PROCAM). // Europ. Heart J.- 1998.- № 19 (Suppl. A, P).- A2 Al 1.
- Avogaro P., Crepaldi G., Enzi G., Tiengo A. Association of hyperlipidemia, diabetess mellitus and mild obesity // Acta Diabetol Lat.- 1967.- № 4.- p. 572−590.
- Bailey C.J., Turner R.C. Metformin // N Engl J Med.- 1996.-№ 334.- p. 574 579.
- Balkau В., Charles M.A., Drivsholm Т., et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome // Diabetes Metab.- 2002.-№ 28.- p. 364−376.
- Bancroft L.W., Peterson J.J., Kransdorf MJ. Cysts, geodes, and erosions // Radiol Clin N Am.- 2004.- № 42.- p. 73−87.
- Barbieri R.I. Hyperandrogenic disorders // Clin Obstet Gynec.- 1990.- № 33 (3).- p. 640−654.
- Barbieri R.L., Hornstein M.D. Hyperinsulinemia and ovarian hyperandrogenism: cause and effect // Endocrinol Metab Clin North Am.-1988.-№ 17.- p. 685−697.
- Bardin T. Fenofibrate and losartan // Ann. Rheum Dis.- 2003 .-№ 62.- p. 497 498.
- Barlow K.A. Hyperlipidemia in primary gout // Metabolism.- 1968.-№ 17.- p. 289−299.
- Barlow K.A., Beilin L.J. Renal disease in primary gout // Q.J.Med.- 1968, — № 37.- p. 79−96.
- Barrett K., Miller M.L., Wilson J.T. Tophaceous gout of the spine mimicking epidural infection- case report and review of the literature // Neurosurgery.- 2001.- № 48(5).-p. 1170−3.
- Bastow M.D., Durrington P.N., Ishola M. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivates (bezaflbrate and fenofibrate) in a double-blind, placebo-controlled trial // Metabolism.- 1988.-№ 37.- p. 217−220.
- BatailIe R., Klein R. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo // Arthritis Rheum.- 1992.- № 35.- p. 282−283.
- Benedek T.G. Correlation of serum acid and lipid concentrations in normal gouty, and atherosclerotic men // Ann Intern Med.- 1967.- № 66.- p. 851−861.
- Berger L., Yu T. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies // Am J Med.- 1975.-№ 59.- p. 605−613.
- Berkowitz D. Blood lipid and uric acid interrelationships // JAMA.- 1964.- № 190.- p. 856−858.
- Berkowitz D. Gout, hyperlipidemia and diabetes interrelationships // JAMA.-1966.-№ 197,-p. 77−80.
- Bernheim C., Ott H., Zahnd G., Martin E. Gout and diabetes 1, gout and its relation with diabetes // Arthritis Rheum.- 1968.- № 4.- p. 360.
- Biasucci L., Liuzzo G., Grillo R., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability // Circulation.-1999.-№ 99.-p. 855−860.
- Biasucci L.M., Giubilato G., Graziani F. Piro M. CRP is or is not a reliable marker of ishaemic heart disease? // Lupus.- 2005.- № 14(9).- p. 752−755.
- Biasucci L.M., Vitelli A., Liuzzo G. Elevated levels of IL-6 in unstable angina// Circulation.- 1996.- № 94.- p. 506−512.
- Bickel C., Rupprecht H.J., Blankenberg S. et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease // Am. J. Cardiol.- 2002.- № 1 (89).- p. 12−17.
- Bieber J.D., Terkeltaub R.A. Gout. On the brink of a novel therapeutic options for an ancient disease // Arthritis Rheum.- 2004.-№ 50.- p. 2400−14.
- Bleyer A.J., Trachtman H., Sandhu J., Gorry M.C., Hart T.C. Renal manifestations of a mutation in the uromodulin (Tamm Horsfall protein) gene // Am J Kidney Dis.- 2003.- № 42.- p 20−26.
- Bo S., Cavallo-Perin P., Gentile L., et al. Hypouricaemia and hyperuricaemia in type 2 diabetes: two different phenotypes // Eur J Clin Invest.-2001.-№ 31(4).-p. 318−321.
- Bogardus C., Lillioja S., Mott D. et al. Relationship between obesity and maximal insulin-stimulated glucose uptake in vivo and in vitro in Pima Indians // J Clin Invest.- 1984.- № 73(3).- p. 800−805.
- Breckenridge A. Hypertension and hyperuricaemia // Lancet.- 1966.-№ l.p. 15−18.
- Burns K.D. Angiotensin II and its receptors in the diabetic kidney // Am. J. Kidney Dis.- 2000.- № 36 (3).- p. 446−467.
- Campion E.W., Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study // Am J Med.- 1987.-№ 82.-p. 421−426.
- Camus J.P. Goutte, diabete, hyperlipemie: un trisyndrom metabolique // Rev Rhumatol.- 1966.- № 33.- p. 10−14.
- Cannon P.J., Svahn D.S., Demartini F.E. The influence of hypertonic saline infusion upon the fractional reabsorbtion of urate and other ions in normal and hypertensive man // Circulation.- 1970, — № 41.- p. 97−108.
- Cannon P.J., Simson W.B., Demartini F.E. Hyperuricemia in primary and renal hypertension //N Engl J Med.- 1966.- № 275.- p. 457−464.
- Cappuccino F.P., Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study // JAMA.- 1993, — № 270.- p. 354−359.
- Cardona F., Tinahones F.J., Collantes E. et al. Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidemia in patients with gout // Ann. Rheum. Dis.- 2005.- № 64 (1).- p. 85−88.
- Caro F.J. Insulin resistance in Obese and Nonobese Man // J Clin Endocrinol Metabolism.- 1991.- № 73.- p. 691−695.
- Chen C.K., Chung K.B., Yeh L., et al. Carpal tunnel syndrome caused by tophaceous gout: CT and MR imaging features in 20 patients //Am J Rheum.- 2000.-№ 175.-p. 655−659.
- Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report // JAMA.- 2003.- № 289(19).- p. 2560−71.
- Choi H.K., Atkinson K., Karlson E.W., et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men // New. Engl. J. Med.- 2004.- № 350.-p. 1093−1103.
- Choi H.K., Atkinson K., Karlson E.W., Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study //Arch Intern Med.- 2005.- № 165.- p. 742−748.
- Considine R., Considine E., Williams C.J. et al. The hypothalamic leptin receptor in humans. Identification of incidental sequence polymorphisms and absence of the dl/db mouse and fa/fa rat mutation // Diabetes.- 1996.- № 19.- p. 992−994.
- Cook D.G., Shaper A.G., Thelle D.S., Whitehead T.P. Serum uric acid, serum glucose and diabetes: relations in a population study // Postgrad Med J.- 1986.-№ 262.-p. 1001−6.
- Cristlieb A.R., Krolewski A.S., Warram J.H., Soeldner I.S. Is insulin the link between hypertention and obesity? // Hypertention.- 1985.- № 7.- II54-II57.
- Crowne D.P., Marlowe D. A new scale of social desirability independent of psychopathology // J Consult Psychol.- I960.- № 24.- p. 349−354.
- Culleton B.F., Larson M. G., Kannel W.B., D. Levy. Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study // Ann. Intern. Med.- 1999.- № 131.- p. 7−13.
- Cusi K., DeFronzo R.A. Metformin: a review of its metabolic effects // Diabetes Review. -1998.- № 689−131.
- Dandona P., Weinstock R., Thusu K., Abdel-Rahman E., Aljada A., Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weightloss // J Clin Endocrinol Metab. -1998.- № 83.- p. 2907−10.
- Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R. Metabolic syndrome. A comprehensive Perspective based on interaction between obesity, diabetes and inflammation // Circulation.- 2005.- № 111.- p. 1448−54.
- Davidson M.B. Clinical implications of insulin resistance syndromes // Am J Med.- 1995.- № 99.- p. 420−426.
- Davies K.J., Sevanian A., Muakkassah-Kelly S.F., Hochstein P. Uric acid -iron ion complexes: a new aspect of the anti-oxidant functions of uric acid // Biochem J.- 1986.- № 235.- p. 747−754.
- De Fronzo R.A., Ferranninni E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease // Diabetes Care.- 1991.- № 14.- p. 173−194.
- Deeg R., Ziegenhorn J. Kinetic enzymatic method for automated determination of total cholesterol in serum // Clin Chem.- 1983.- № 29.- p. 17 981 802.
- Denis G., Launay M.P. Carbohydrate intolerance in gout // Metabolism.- 1969.-№ 18.-p. 770−775.
- Denke M.A. Metabolic syndrome // Current Atherosclerosis Reports.-2002.-№ 4.- p. 444−447.
- Despres J.P., Moorjani S., Lupien P.J. et al. Regional distribution of body fat, plasma insulin, plasma lipoproteins, and cardiovascular disease // Arteriosclerosis.- 1990.- № 10.- p. 497−511.
- Diamond H.S., Paolino J.S. Evidence for a postsecretory reabsorbtive site for uric acid in man // J Clin Invest.- 1973.- № 52.- p. 1491−9.
- Drum D.E., Goldman P.A., Jankowski C.B. Elevation of serum uric acid as a clue to alcohol abuse // Arch Intern Med.- 1981.- № 141.- p. 477−479.
- Ducimetiere P., Eschwege E., Papoz L. et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population // Diabetologia.- 1980.- № 19.- p. 205−210.
- Duffy W.B., Sennekjian H.O., Knight T.F., Weinman E.J. Management of asymptomatic hyperuricemia//JAMA.- 1981.-№ 246.-p. 2215−6.
- Eastmond C.J., Garton M., Robins S., Riddoch S. The effects of alcoholic beverages on urate metabolism in gout sufferers // Br J Rheumatol.- 1995.-№ 34.- p. 756−759.
- Edwards N.L. Gout: clinical and laboratory features. In Klippel J.H., th
- Crofford L., Stone J.H., et al, eds. Primer on the Rheumatic Diseases.- 12 ed. Atlanta, Ga: Arthritis Foundation, 2001.- p. 313−319.
- Edwards N.L., Recker D., Aroizo D., Fox I.H. Enhanced purine salvage during allopurinol therapy: an important pharmacologic property in humans // J Lab Clin Med.- 1981.-№ 98.-p. 673−683.
- Eidemak I., Felt-Rasmussen В., Kanstrup I.-L., et al. Insulin resistance and hyperinsulinemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity // Diabetologia.- 1995.- № 38.- p. 565.
- Emmerson B. Hyperlipidemia, hyperuricaemia and gout // Ann. Rheum. Dis.- 1998.- № 57.- p. 509−510.
- Engelhardt H.T., Wagner E.L. Gout, diabetes mellitus and obesity, a poorly recognized syndrome // South Med J.-1950.- № 43 p. 51−53.
- Enomoto A., Kimura H., Chairoungdua A., Shigeta Y., Jutabha P., Cha S.H., et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels // Nature.- 2002.-№ 417.- p. 447−452.
- Ewing J.A. Detecting alcoholism: The CAGE questionnaire // JAMA.-1984.-№ 252.- p. 1905−7.
- Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) // JAMA.- 2001.- № 285(19).- p. 2486−97.
- Faccini F., Ida Chen Y.D., Hollenbeck C.B., Reaven G.M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration // JAMA.- 1999.- № 266.- p. 3008−11.
- Fagan T.C., Deedwania P.C. The cardiovascular dysmetabolic syndrome // Am. J. Med.- 1998.- № 105.- p. 77S-82S.
- Faller J., Fox I.H. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover // N Engl J Med.- 1982.- № 307.- p. 1598−1602.
- Fam A.G. Gout in the elderly: clinical presentation and treatment // Drug Aging.- 1998.-№ 13.-p. 229−243.
- Fam A.G. Gout, diet, and the insulin resistance syndrome // J Rheumatol.- 2002.- № 29.- p. 1350−5.
- Fang J., Alderman M. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971−1992. National Health and Nutrition Examination Survey // JAMA.- 2000.- № 238.- p. 2404−10.
- Feher M.D., Hepburn A.L., Hogarth M.B., Ball S.G. and Kaye S.A. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricemia and gout // Rheumatol.- 2003.- № 42 (2).- p. 321−325.
- Feldman E.B., Wallace S.L. Hypertriglyceridemia in gout // Circulation.-1964.-№ 29.-p. 508−513.
- Ferns G.A., Lanham J., Dieppe P., Galston D.J. A DNA polymorphism of an apoprotein gene associates with the hypertriglyceridemia of primary gout // Hum Genet.- 1988.-№ 78.-p. 55−59.
- Festa A., D’Agostino R. J., Howard G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS) // Circulation. -2000.- № 102.- p. 42- 47.
- Flixer D., Pacini G., Engelleiter R., et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease // Kidney Int.- 1998.- № 53.-p. 1343.
- Ford E.S., Cooper R.S. Risk factors for hypertension a national cohort study//Hypertension.- 1991.-V.18.- N5.- p. 598−606.
- Fournier A.M., Gadia M.T., Kubrusly D.B. et al. Blood pressure, insulin, and glycemia in nondiabetic subjects // Am. J. Med.- 1986.- № 80.- p. 861 864.
- Freedman D. S, Willamson D.F., Gunter E.W., Byers T. Relation of serum uric acid to mortality and ishemic heart disease. The NHANES 1 Epidemiologic Follow-up Study//Am. J. Epidemiol.- 1995.-№ 141(7).-p. 637−644.
- Freemont A.J. Microscopic analysis of synovial fluid the perfect diagnostic test // Ann Rheum Dis.- 1996.- № 55.- p. 695−697.
- Friedewald W.T., Levy R.S., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge // Clin Chem.- 1972.- № 18.- p. 499−502.
- Galvan A.Q., Ferrannini E. Renal effects of insulin in man // J Nephrol.-1997.-№ 10(4).-p. 188−191.
- Galvan A.Q., Natali A., Baldi S. et al. Effect of insulin on uric acid secretion in humans // Am J Physiol.- 1995.- № 268.- p. E1-E5.
- Garcia P.J., Mateos A.F., Munoz S.A.: Renal handling of uric acid in normal subjects by means of the pyrazinamide and probenicid tests // Nephron.-1983.- № 35.- p. 183−186.
- Genest J.J., Jenner J.L., McNamara J.R. et al. Prevalence of lipoprotein (a) excess in coronary artery disease // Am. J. Cardiol.- 1991.- № 67.- p. 1039−45.
- German D. A simple measurement to monitor the size of gouty tophi and rheumatoid nodules // J Clin Rheumatol.- 1997.- № 3, — p. 45−46.
- Gertler M.M., Garn S.M., Levine S.A. Serum uric acid in relation to age and physique in health and in coronary heart disease // Ann. Intern. Med.- 1951.-№ 34.- p. 1421−31.
- Gibson Т., Grahame R. Gout and hyperlipidaemia // Ann Rheum Dis.-1974.-№ 33.-p. 298−303.
- Gibson Т., Rodgers A.V., Simmonds H.A., Toseland P. Beer drinking and its effect on uric acid // Br J Rheumatol.- 1984.- № 23.- p. 203−209.
- Ginsberg M.H., Kozin F., Chow D., May J., Skosey J.L. Adsorption of polymorphonuclear leukocyte lysosomal enzymes to monosodium urate crystals // Arthritis Rheum.- 1977.- № 20.- p. 1538−42.
- Glass C.K., Witztum J.L. Atherosclerosis: the road ahead // Cell.- 2001 .-№ 104.- p. 503−516.
- Glueck C.J., Wang P., Fontaine R., Tracy Т., Sieve-Smith L. Metformin induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome // Metabolism.- 1999.- № 48.- p. 511 519.
- Godsland I.F., Stevenson J.C. Insulin resistance: syndrome or tendency? // Lancet.- 1995.- № 346.- p. 100−103.
- Goldberg R.B., Capuzzi D. Lipid disorders in type 1 and type 2 diabetes // Clin. Lab. Med.- 2001, — № 21.- p. 147−171.
- Goodpaster B.H., Thaete F.L., Kelley D.E. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type II diabetes mellitus // Am J Clin Nutr.- 2000.- № 71.- p. 885−892.
- Goodson N.J., Symmons D.B.M., Scott D.G.I., et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis // Arthritis Rheum.- 2005.- № 52 (8).- p. 2293−9.
- Gotfredsen A., McNair P., Cristiansen C., Transbol I. Renal hypouricaemia in insulin treated diabetes mellitus // Clin Chim Acta.- 1982.- № 120(3).-p. 355−361.
- Grahame R., Scott J.T. Clinical survey of 354 patients with gout // Ann. Rheum. Dis.- 1970.- № 29.- p. 461−468.
- Grant P.J. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes // Diabetes Care.- 1996.-№ 19. p. 64−66.
- Grimaldi A., Heurtier A. Epidemiology of cardiovascular complication of diabetes // Diabetes Metab.- 1999.- № 25 (3).- p. 12−20.
- Grodzicki Т., Palmer A., Bulpitt C.J., Incidence of diabetes and gout in hypertensive patients during 8 year of follow-up // J Hum Hypertens.- 1997.- № 11.-p. 583−585.
- Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome // Am. J. Cardiol.- 1999.- № 83.- p. 25F-29 °F.
- Grundy S.M., Brewer H.B., Cleeman J.I. Definition of metabolic syndrome. Report of the national heart, lung, and blood institute. American heart association conference on scientific issue related to definition // Circulation.- 2004.-№ Ю9 p. 433−438.
- Grundy S.M. Inflammation, metabolic syndrome, and diet responsiveness//Circulation.-2003.- № 108.-p. 126−128.
- Guan M.P., Xue Y.M., Shen J. et al. Serum uric acid in type 2 diabetic patients complicated by stroke // Di Yi Jun Yi Da Xue Xue Bao.- 2002.- № 22(1).- p. 70−71.
- Guerne P.A., Terkeltaub R., Zuraw В., Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes // Arthritis Rheum.- 1989.- № 32.- p. 1443−52.
- Gutman A.B. The past four decades of progress in the knowledge of gout, with an assessment of the present status // Arthritis Rheum.- 1973.- № 16.- p. 431−445.
- Gutman A.B. Views on the pathgenesis and management of primary gout 1971 // J Bone Joint Surg.- 1972.-№ 54A. p. 357−372.
- Gwozdziewiczova S., Lichnovska R., Yahia R.B., Chlup R., Hrebicek J. TNF-a in development of insulin resistance and other disorders in metabolic syndrome // Biomed Papers.- 2005.- № 149(1).- p. 109−117.
- Haffner S.M., Gonzalez C., Miettinen H. et al. A prospective analysis of the HOMA model: the Mexico City Diabetes Study // Diabetes Care.- 1996.- № 19.-p. 1138−41.
- Haffner S.M., Stern M., Hazuda H.P. et al. Cardiovascular risk factors in confirmed prediabetic individuals // JAMA.- 1990.-№ 263.- p. 2893−8.
- Haffner S.M. Epidemiology of insulin resistance and its relation to coronary artery disease // Am J Cardiol.- 1999.- № 84.- p. 11J-4J.
- Hall A.P., Barry P.E., Dawber T.R. et al. Epidemiology of gout and hyperuricemia: A long-term population study // Am J Med.- 1967.- № 42.- p. 27−37.
- Halla J.T., Ball G.V. Saturnine gout: a review of 42 patients // Semin Arthritis Rheum.- 1982.-№ 11.-p. 307−314.
- Halle M., Berg A., Northoff H. et al. Importance of TNF-alfa and leptin in obesity and insulin resistance: a hypothesis on the impact of physical exercise // Exp Immunol Rev.- 1998.- № 4.- p. 77−94.
- Hansen N.E. The anemia of chronic disorders: a bag of unresolved questions // Scand J Haematol.- 1983.- № 31.- p. 397−402.
- Нага H., Egusa G., Yamakido M. Incidence of non-insulin-dependent diabetes mellitus and its risk factors in Japanese-Americans living in Hawaii and Los Angeles// Diabetic Medicine.- 1996.-№ 13.-p. S133-S142.
- Haupt E., Knick В., Koschinsky Т., Liebermeister H., Schneider J., Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin // Diabetes Metab.- 1991.- № 17.- p. 224−231.
- Hausch R., Wilkerson M., Singh E., Reyes C., Harrington T. Tophaceous gout in the thoracic spine presenting as back pain and fever // J Clin Rheumatol.-1999.-№ 5.- p. 335−341.
- Hayden M.R., Tyagi S.C. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle // Nutrition Metabolism.- 2004.- № 1(10).
- Hediger M.A., Johnson R.J., Miyazaki H., Endou H. Molecular Physiology of Urate Transport // Physiology.- 2005, — № 20.- p. 125−133.
- Hench P. S. The diagnosis of gout and gouty arthritis // J Lab Clin Med.-1936.-№ 220.-p. 48−50.
- Herman J.B., Mount F.W., Medalie J.H., et al. Diabetes prevalence and serum uric acid: Observations among 10,000 men in a survey of ischemic heart disease in Israel //Diabetes.- 1967.- № 16.- p. 858−868.
- Hochberg M.C., Change R.W., Dwosh I., et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis // Arthritis Rheum.- 1992.- № 35.- p. 498−502.
- Holmes W.E., Kelley N.W., Wyngaarden J.B. The kidney and uric acid excretion in man // Kidney Int.- 1972.- № 2.- p. 115−118.
- Hotamasligil G.S. Molecular mechanism of insulin resistance and the role of the adipocyte // Int J Obes.- 2000.- № 24(Suppl. 4).- p. 23−27.
- Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance// Science.- 1993.- № 259, — p. 87−91.
- Howard B.V. Lipoprotein metabolism in diabetes mellitus // J.Lipid. Res.- № 8.-p. 613−628.
- Hrebicek J., Janout V., Malincikova J. et al. Detection of insulin resistance by simple quantitative sensitivity check index QUICKI for epidemiological assessment and prevention // J Clin Endocrinol Metab.- 2002.- № 87.- p. 144−147.
- Huber N. Zur Verwerthung der Rontgen-Strahlen im Gebiete der inneren Medicine (The use of x-rays in internal medicine) // Dtsch Med Wochenschr.- 1896.-№ 22.-p. 182−184.
- Hundal RS., Krssak M., Dufour S., Laurent D., Lebon V., Chandramouli V., et al. Mechanism by which metformin reduces glucose production in type 2 diabetes // Diabetes.- 2000.- № 49.- p. 2063−9.
- Ichida K., Hosoyamada M., Hisatome I., Enomoto A., Hikita M., Endou H., et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan influence of URAT1 gene on urinary urate excretion // J Am Soc Nephrol.-2004.-№ 15.-p. 164−173.
- Iwatani M., Wasada Т., Katsumori K. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetic // Diabetologia.-2000,-№ 43.-p. 814−815.
- Janssens H.J.E.M., van de Lisdonk E.H., Bor H., van den Hoogen H.J.M., Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care // Family Practice.- 2003.- № 20 (4).- p. 413−417.
- Jiao S., Kameda K., Matsuzava Y., Tarui S. Hyperlipoproteinaemia in primary gout: Hyperlipoproteinaemic phenotype and influence of alcohol intake and obesity in Japan // Ann.Rheum. Dis.- 1986.- № 45.- p. 308−313.
- Johansen K. Efficacy of metformin in the treatment of NIDDM. Metaanalysis // Diabetes Care.- 1999.- № 22.- p. 33−37.
- Johnson R., Kivlighn S., Kim Y.-G. et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease and renal disease // Am J Kidney Dis.- 1999.- № 33.- p. 225−234.
- Johnson R.J., Kang D.H., Feig D., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? // Hypertension.-2003.-№ 41.- p. 1183−90.
- Johsson S.W., Backman C., Johnson О., Karp K., et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis // J Rheumatology.- 2001.- № 28.- p. 2597−2602.
- Jousilahti P., Vartiainen E., Tuomilehto J., et al. Sex, age, cardiovascular risk factors, and coronary heart disease: A prospective follow-up study of 14,786 middle-aged men and women in Finland // Circulation.- 1999.- № 99. p. 1165.
- Julius S., Gudrabrandsson Т., Jamerson K., Andersson O. The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension // Blood Pressure.- 1992.- № 1.- p. 9−19.
- Kahn A.M. Indirect coupling between sodium and urate transport in the proximal tubule // Kidney Int.- 1989.- № 36.- p. 378.
- Kaneko K., Fujimori S., Akaoka I. Changes caused by ethanol intake on metabolism of hypouricemic agents (combination of allopurinol and benzbromarone) //Adv Exp Med Biol.- 1991.-№ 309.-p. 139−142.
- Kaplan N.M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension // Arch Intern Med.- 1989.- № 149.-p. 1514−20.
- Katz A., Nambi S.S., Mather K. et al. Quantitative insulin sensitivity check Index: a simple, accurate method for assessing insulin sensitivity in humans // J Clin Endocrinol Metab.- 2000.- № 85.- p. 2402−10.
- Kern P.A., Ranganathan S., Li C., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance // Am J Physiol.- 2001.- № 280.- p. E745-E751.
- Khaodhiar L., McCowen K.C., Blackburn G.L. Obesity and comorbid conditions // Clin. Cornestone.- 1999.- № 2, 3.- p. 17−31.
- Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: An Update // Ann Intern Med.- 2002.- № 137.- p. 25−33.
- Kirpichnikov D., Sowers J.R. Diabetes mellitus and diabetes-associated vascular disease // Trends Endocrinol Metab.- 2001.- № 12.- p. 225−230.
- Kissebah A.H. Central obesity: measurement and metabolic effects // Diabetes Rev.- 1997.- № 5.- p. 8−20.
- Koening W. Atherosclerosis involves more than just lipids: focus on inflammation // Eur Heart J.- 1999 (Suppl T).- p. T19-T26.
- Kuller L.H., Tracy R.P., Shaten J., et al. for MRFIT research group. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study//Am. J. Epidemiol.- 1996, — № 144.- p. 537−547.
- Kuzell W.C., Schaffarzick R.W., Naugler W.E. et al. Some observations on 520 gouty patients // J.Chronic. Dis.- 1995.- № 2, — p. 645−669.
- Kwiterovich P.O. Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review // Am. J. Cardiol.- 2000.- № 86 (12).- p. 5−10.
- Lagrand W.K., Visser C.A., Hermens W.T.et al. C-reactive protein as cardiovascular risk factor: more than an epiphenomenona // Circulation 1999.- № 1000.-p. 96−102.
- Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men // JAMA.-2002.-№ 288.-p. 2709−16.
- Lamarche В., Lemieux I., Despres J.P. The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, pathophysiology, and therapeutic aspects // Diabetes Metab.- 1999.- № 25.- p. 199−211.
- Lane P. Drug-induced gout // Br. Med J.- I960.- № 2.- p. 1383−4.
- Langewitz W., Kiss A., Schachinger H. From perception to symptom — from symptom to diagnosis. Somatoform disorders as a communication phenomenon // J Suisse Med.- 1988, — № 128.- p. 231−244.
- Laragh J.H., Heinemann H.O. Demartini F.F. Effect of chlorothiazide on electrolyte transport in man- its use in the treatment of edema of congestive heart failure, nephrosis, and cirrhosis // JAMA.- 1958.- № 166.- p. 145−152.
- Large V., Beylot M. Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin // Diabetes.- 1999.- №> 48.- p.1251−7.
- Larsen A., Dale К., Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films // Acta Radiol 1977.- № 18.- p. 481−491.
- Larsson I., Lindroos A.K., Lystig T.C. Three definition of the metabolic syndrome: relations to mortality and atherosclerotic morbidity // Metabolic syndrome and related disorders.- 2005.- № 3(2).- p. 102−112.
- Lawrence R.C., Helmick C.G., Arnett F.C., Deyo R.A., Felson D.T., Giannini E.H., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States // Arthritis Rheum.- 1998.- № 41.- p. 778−799.
- Lehto S., Niskanen L., Ronnemaa Т., Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus // Ann Epidemiol.- 1996.- № 6.- p. 331−340.
- Leyva F., Anker S., Swan J.W., et al. Serum uric acid as an index of impaired oxidative metabolism in chronic renal failure // Eur Heart J.- 1997.- № 8.- p. 858−865.
- Lieber C.S., Jones D.P., Losowsky M.S., Davidson C.S. Interrelation of uric acid and etanol metabolism in man // J Clin Invest.- 1962.- № 41.- p. 1863−70.
- Lillioja S., Young A.A., Culter C.L. et al. Skeletal muscle capillary dencity and fiber type are possible determinants of in vivo insulin resistance in man // J. Clin. Invest.- 1987.- № 80.- p. 415−424.
- Lin J.L., Huang P.T. Body lead stores and urate excretion in men with chronic renal disease // J Rheumatol.- 1994.- № 21.- p. 705−709.
- Lin K.C., Lin H.Y., Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen // J Rheum.- 2000.- № 27.- p. 1045−50.
- Lind L., Lithell H. Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia //Am. Heart. J.- 1993.- № 125.- p. 1494−7.
- Liuzzo G., Biasucci L.M., Gallimore J.R. et al. The prognostic value of C-reactive protein and serum amiloid A protein in severe unstable angina // N Engl J Med.- 1994.-№ 331.- p. 417.
- Li-Yu J., Clauburne G., Sieck M., et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? // J Rheumatol.- 2001.- № 28.- p. 577−580.
- Loffler W., Grobner W., Medina R., Zollner N. Influence of dietary purines on pool size, turnover, and excretion of uric acid during balance conditions. Isotope studies using 15-N-uric acid // Res Exp Med.- 1982.- № 181.- p. 113−123.
- Logan J.A., Morrison E., McGill P.E. Serum uric acid in acute gout // Ann Rheum Dis.- 1997.- № 56(11).- p. 696−697.
- MacLean P. S, Vadlamudi S., MacDonald K. G et al. Impact of insulin resistance on lipoprotein subpopulation distribution in lean and morbidly obese nondiabetic women // Metabolism.- 2000.- № 49.- p. 285−292.
- Мак R.H., De Fronzo R.A. Glucose and insulin metabolism in uremia // Nephron.- 1992.- № 61, — p. 377.
- Manicardi V., Camellini L., Bellodi G., Ferrannini E. Evidence for an association of high blood pressure and hyperinsulinrmia in obese man // J. Clin. Endocrinol. Metab.- 1986.- № 62.- p. 1302 -4.
- Masanori E., Yoshiki N., Kiyoshi M., Yoshikazu H. et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas // Diabetes Care.- 1999.- № 22.- p. 818−822.
- Matsuno H., Yudoh K., Hanyu Т., et al. Quantitative assessment of hand radiographs of rheumatoid arthritis: interobserver variation in a multicenter radiographic study // J Ortop Sci.- 2003.- № 8(4).- p. 467−473.
- Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia.- 1985.- № 28.- p. 41219.
- Mayne J.G. Pathological study of the renal lesions found in 27 patients with gout // Ann Rheum Dis.- 1956.-№ 15.-p. 61−62.
- Mazzali M., Hughes J., Kim Y.G., et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism // Hypertension.-2001.- № 38.-p. 1101−6.
- McCarty D.J. Jr. The inflammatory reaction to microcrystalline sodium urate // Arthritis Rheum.- 1965.- № 8.- p. 726−735.
- Mclnnes I.B., Rheumatoid arthritis: from bench to bedside // Rheum Dis Clin North Am.- 2001.- № 27.- p. 373−387.
- Mehnert H., Sewering H., Reichstein W., Vogt H. Friiherfassung von Diabetikern in Munchen // Dtsch med Wschr.- 1968.- № 93.- p. 2044−50.
- Meigs J.B., Mittleman M.A., Nathan D.M. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study // JAMA.- 2000.- № 283.- p. 221−228.
- Melloni P., Vails R., Yuguero M., Saez A. An unusual case of tophaceous gout involving the anterior cruciate ligament // Arthroscopy.- 2004- № 20(9).-p. 117−121.
- Messerli F.H., Frohlich E.D., Dreslinski G.P., Suarez D.H., Aristimuno G.G. Serum uric acid in essential hypertension: an indicator of renal vascular involvement // Arch Intern Med.- 1980.- № 93.- p. 817−821.
- Mikkelsen W.M., Dodge H.J., Valkenburg H. The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia: Tecumseh, Michigan, 1959−1960 //Am J Med.- 1965.- № 39.-p. 242−251.
- Mikkelsen W.M. The possible association of hyperuricemia and/or gout with diabetes mellitus // Arthritis Rheum.- 1965.- № 8.- p. 853−864.
- Modan M., Halkin H., Almog S. et al. Hyperinsulinemia: a link between hypertention, obesity and glucose intolerance // J. Clin. Invest.- 1985.- № 75.- p. 809−817.
- Monu J.U.V., Pope T.L. Jr. Gout: a clinical and radiologic review // Radiol Clin N Am.- 2004.- № 42.- p. 169−184.
- Moriwaki Y., Yamamoto Т., Takahashi S., Tsutsumi Z., Higashino K., Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia // Ann Rheum Dis.- 1995.- № 54.- p. 351−354.
- Morrow D.A., Rifai N., Antman E.M. et al. C-reactive protein is a potent predictor of mortality independentally of and in combination with troponin in acute coronary syndrome: a TIMIIIA study // J Am Coll Cardiol.- 1988.- № 31.- p. 1460−5.
- Muscelli E., Natali A., Bianchi S., et al. Effects of insulin on renal sodium and uric acid handling in essential hypertension // Am J Hypertens.- 1996.- № 9.- p. 746−752.
- Musgrave G. De arthritide symptomatica dissertatio.- Geneva: G de Tournes, 1723 p.
- Myers A., Epstein F.H., Dodge H.J. et al. The relationship of serum uric acid to risk factors in coronary heart disease // Am J Med.- 1968.- № 45.- p. 520−528.
- Nagi D.K., Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups // Diabetes Care.- 1993.- № 16(4).- p. 621 629.
- Nakae J., Biggs W.H. Ill, Kitamura T. et al. Regulation of insulin action and pancreatic betacell function by mutated alleles of the gene encoding forkhead transcription factor Foxol // Nat Genet.- 2002.- № 32.- p. 245−253.
- Nakagawa Т., Mazzali M., Kang D-H. Hyperuricemia Causes Glomerular Hyprtrophy in the Rat // Am. J. Nephrol.- 2002.
- Nauck M., Maerz W., Wieland H. New immunoseparation-based homogenous assay for HDL-cholesterol compared with three homogenous and two heterogeneous methods for HDL-cholesterol // Clin Chem.- 1998.- № 44.- p. 144 351.
- Nesto R.W. Obesity. A major component of the metabolic syndrome // Tex Heart Inst J.- 2005.- № 32(3).- p. 387−389.
- Nicholls A., Scott J.T. Effect of weight-loss on plasma and urinary levels of uric acid // Lancet.- 1972.- ii.- p. 1223−4.
- Nicholls A., Snaith M.L., Scott J.T. Effect of oestrogen therapy on plasma and urinary levels of uric acid // Brit M J.- 1973.- № 1.- p. 449.
- North K.E., Almasy L., Goring H.H. et al. Linkage analysis of factors underlying insulin resistance: Strong Heart Family Study // Obes Res.- 2005.- № 13(11).- p. 1877−84.
- Oclcene I.S., Mathews C.D., Rifai N. et al. Validity and classification accuracy of serial nigh-sensitive C-reactive protein measurements in healthy adults // Clin Chem.- 2001.- № 47.- p. 444−450.
- Ohno I., Ichida K., Okabe H. et al. Frequency of gouty arthritis in patients with end-stage renal disease in Japan // Internal Med.- 2005.- № 44(7).- p. 706−709.
- Onat A., Ceyhan K., Basar O., et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels: a prospective and cross-sectional evaluation// Atherosclerosis.- 2002.-№ 165.- p. 285−292.
- Oren B.G., Rich M., Belle M.S. Chlorothiazide (Diuril) as a hyperuricacidemic agent // JAMA.- 1958.- № 168.- p. 2128−9.
- Orho-Melander M., Klannemark M., Svensson M.K. et al. Variants in the calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels // Diabetes.- 2002.- № 51.- p. 2658−64.
- Padova J., Patchefsky A., Onesti G., et al. The effect of glucose loads on renal uric acid excretion in diabetic patients // Metabolism.- 1964.- № 13.- p. 507 512.
- Park Y-B., Ahn C-W, Choi H.K., et al. Atherosclerosis in rheumatoid arthritis. Morphologic evidence obtained by carotid ultrasound // Arthritis Rheum.-2002.-№ 46.-p. 1714−9.
- Pascual E. Persistence of monosodium urate crystals and low grade inflammation in the synovial fluid of patients with untreared gout // Arthr Rheum.-1991.-№ 42 (2).-p. 141−145.
- Pascual E., Battle-Gualda E., Martinez A., et al. Synovial fluid analysis for diagnosis of intercritical gout//Ann Intern Med.- 1999,-№ 131,-p. 758−759.
- Perry I.J., Wannamethee S.G., Walker M.K. et al. Prospective study of risk factors for development diabetes in middle aged British men // BMJ.- 1995.- № 310.-p. 560−564.
- Pfeifle В., Ditschuneit H. Effect of insulin on groth of cultured human arterial smooth muscle cells // Diabetologia.- 1981.- № 20.- p. 155−158.
- Plant M., Saklatvala J., Jones P., Dawes P. Prediction of radiographic damage in hands and feet in rheumatoid arthritis by clinical evaluation // Clin Rheum.- 1994.-№ 13.-p. 487−491.
- Polonsky K.S., Given B.D., Hirsch L.J., et al. Abnormal pattern of insulin secretion in non-insulin-dependent diabetes mellitus // N Engl J Med.- 1988.-№ 318.-p. 1231−9.
- Pouliot M., James M.J., McColl S.R., Naccache P.H., Cleland L.G. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes // Blood.- 1998.-№ 91.-p. 1769−76.
- Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus // JAMA.- 2001.-№ 286.- p. 327−334.
- Puig J.G., Fox I.H. Ethanol-induced activation of adenine nucleotide turnover. Evidence for a role of acetate // J Clin Invest.- 1984.- № 74.- p. 936−941.
- Puig J.G., Ruilope L.M. Uric acid as a cardiovascular risk factor in arterial hypertension // J Hypertens.- 1999, — № 17.- p. 869−872.
- Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland // Diabetes Care.- 1979.- № 2.- p. 131−141.
- Rader D.J. Inflammatory markers of coronary risk // N Engl J Med.-2000.- № 343.- p. 1179−82.
- Radic M.T., Valkenburg H.A., Davidson R.T. et al. Observations on the natural history of hyperuricemia and gout. I. An eighteen year follow-up of nineteen gouty families // Am J Med.- 1964.- № 37, — p. 862−871.
- Rafey M.A., Lipkowitz M.S., Leal-Pinto E., Abramson R.G. Uric acid transport // Curr Opin Nephrol Hypertens.- 2003.- № 12.- p. 511−516.
- Raison J., Safar M., Asmar R.E. et al. Sex dependent of body fat distribution and fluid volumes in hypertension // Kidney Int.- 1988.- № 25.- p. 122 124.
- Ralston S.H., Capell H.A., Sturrock R.D. Alcohol and response to treatment of gout//BMJ.- 1988.- № 296.- p. 1641−2.
- Randeree H.A., Omar M.A.K., Motala A.A., Seedat M.A. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure // Diabetes Care.- 1992.- № 15.- p. 1258−63.
- Rapado A. Relationship between gout and arterial hypertension // Adv. Exp. Med. Biol.- 1974.- № 41.- p. 451−459.
- Rau R, Wassenberg S. Scoring Methods // J Rheum.- 2002, — № 29(4).-p. 653−655.
- Reaven G.M. Do high carbohydrate diets prevent the development or attenuate the manifestations (or both) of syndrome X? A viewpoint strongly against // Curr Opin Lipidol.- 1997.- № 8.- p. 23−27.
- Reaven G.M. Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease // Circulation.- 2002.- № 106.-p. 286−288.
- Reaven G.M. Pathophysiology of insulin resistance in human diseases // Physiol Rew.- 1995.- № 75.- p. 473−486.
- Reaven G.M. Role of insulin resistance in human disease // Diabetes.-1988.- № 37, — p. 1595−1607.
- Resnick H.E., Jones K., Ruotolo G., et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study // Diabetes Care.- 2003.- № 26.- p. 861— 867.
- Reynaud M., Schwan R., Loiseaux-Meunier M.N., Albuisson E., Deteix P. Patients admitted to emergency services for drunkenness: moderate alcohol users or harmful drinkers? //Am J Psychiatry.- 2001.- № 158.- p. 96−99.
- Rho Y.H., Choi S.J., Lee Y.H., et al The prevalence of metabolic syndrome in patients with gout: a multicenter study // J Korean Med Sci.- 2005.- № 20.-p. 1029−33.
- Ridker P.M. Evaluating novel cardiovascular risk factor can we better predict heart attack? // Ann Intern Med.- 1999.- № 130.- p. 933−937.
- Ridker P.M. High-sensitive C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease // Circulation.- 2001.-№ 103.-p. 1813−8.
- Ridker P.M., Buring J.E., Cook N.R., et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women // Circulation.- 2003.- № 107.- p. 391— 397.
- Rifai N., Bachorik P. S., Albers J.J. Lipids, lipoproteins and apolipoproteins. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry.- 3rd ed. Philadelphia: W. B Saunders Company, 1999, p. 809−861.
- Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated highsensitivity C-reactive protein assay // Clin Chem.- 1999.- № 45.- p. 2136−41.
- Rifkin H. Diabetes Mellitus: Theory and Praktise (4th Ed.), 1992.
- Roberts W.L., Moulton L., Law T.C. et al. Evaluation of nine automated high sensitive C-reactive protein methods: implications for clinical and epidemiological applications // Clin Chem.- 2000.- № 47.- p. 418−423.
- Roberts W.L., Sedrick R., Moulton L. et al. Evaluation of four automated high-sensitive C-reactive protein methods- implications for clinical and epidemiological applications // Clin Chem.- 2000.- № 46.- p. 461−468.
- Robinson A.C., Burke J., Robinson S., Johnston D.G., Elkeles R.S. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control // Diabetes Care.- 1998.- № 21.- p. 701 705.
- Rodnan G.P. A gallery of gout // Arthritis. Rheum.- 1968.- № 4.- p. 520−528.
- Rose H.G., Yalow R.S., Schweitzer P., Schwartz E. Insulin as a potential factor influencing blood pressure in amputees // Hypertension.- 1986.- № 8.- p. 793 800.
- Ross R. Atherosclerosis an inflammatory disease // N. Engl. J. Med.-1999.- № 340.-p. 115−126.
- Roubenoff R., Klag M.J., Mead L.A., et al. Incidence and risk factors for gout in white men // JAMA.- 1991.- № 266.- p. 3004−7.
- Ruilope L., Garcia-Puig J. Hyperuricemia and renal function // Curr Hypertension Rep.- 2001.- № 3.- p. 197−202.
- Saag K.G., Mikuls T.R. Recent advances in the epidemiology of gout // Curr Rheumatol Rep.- 2005.- № 7.- p. 235−241.
- Sartoris D.J., Resnik D. Radiological changes with aging in relation to bone disease and arthritis. In Clinics in rheumatic diseases // Editor W.F. Kean, London Philadelfia Toronto.- 1986.- № 12 (1).- p. 181−226.
- Sattar N., McCarey D.W., Capel H., et al. Explaining how «high -grade» systemic inflamation accelerates vascular risk in rheumatoid arthritis // Circulation.-2003.-№ 108.-p. 2957−63.
- Scheen A.J. Clinical pharmacokinetics of metformin // Clin Pharmacokinet.- 1996, — № 30.- p. 359−371.
- Schumacher H.R. Hyperuricemia and Gout: Clinical Implication and Treatment Challenges of a Chronic Disease // JointandBone.org.- 2004.
- Schumacher H.R., Boice J.A., Daikh D.I., et al. Randomised double blind trial of etoricoxib and indometacin of acute gouty arthritis // BMJ.- 2002.- № 324.-p. 1488−92.
- Schumacher H.R. Jr. Crystal-induced arthritis: an overview // Am J Med.- 1996.-№ 100.-p. 46S-52S.
- Schumacher R.H., Edwards L.N. Jr, Perez-Ruiz F., et al. Outcome measures for acute and chronic gout // J Rheumatol.- 2005.-№ 32 (12).- p. 2452−5.
- Scott J.T., Holloway Y.P., Glass H.I., Arnott R.N. Studies of uric acid pool size and turnover rate // Ann Rheum Dis.- 1969.- № 28.- p. 366−373.
- Seegmiller J.E., Howell R.R., Malawista S.E. The inflammatory reaction to sodium urate // JAMA.- 1962, — № 180.- p. 469−475.
- Seidell J. Obesity in Europe // Obes Res.- 1995.- № 3 (Suppl 2).- p. 89s-93 s.
- Semplicini A., Del Prato S., Giusto M., Campagnolo M., Palatini P., Rossi G.P., et al. Short-term effects of metformin on insulin sensitivity and sodiumhomeostasis in essential hypertensives // J Hypertens Suppl.- 1993.- № 11 (Suppl 5).- p. lib-Ill.
- Shapiro M., Hyde L. Hyperuricemia due to pyrazinamide // Am J Med.-1957.-№ 23.-p. 596−599.
- Sharp J.T., Young D.Y., Bluhm G.B., et al How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? // Arthritis Rheum.- 1985.- № 28.- p. 1326−35.
- Sharpe C.R. A case-control study of alcohol consumption and drinking behavior on patients with acute gout // Can Med Assoc J.- 1984.- № 131.- p. 563 567.
- Sharpe P.C. Biochemical detection and monitoring of alcohol abuse and abstinence // Ann Clin Biochem.- 2001.- № 38.- p 652−664.
- Sillanaukee P., Lof K., Harlin A., Matensson O., Brandt R., Seppa K. Comparison of different methods for detecting carbohydrate-deficient transferring // Alcohol Clin Exp Res.- 1994.- № 18.- p. 1150−5.
- Sims E.A. Are there persons who obese, but metabolically healthy? // Metabolism.- 2001.- № 50(12).- p. 1499−1504.
- Stene-Larsen G. Alcohol-induced hyperlipemia. Hypertension and extreme hypercholesterolemia/hypertriglyceridemia in a patient with hidden alcohol abuse//Tidsskr Nor Laegeforen.- 1989.-№ 10, 109(4).-p. 458−459.
- Stout R.W., Beierman E.I., Ross R. The effect of insulin on the proliferation of cultured primate arterial smooth muscle cells // Circ Res.- 1975.- № 36.-p. 319−327.
- Stout R.W. The relationship of abnormal circulating insulin levels to atherosclerosis // Atherosclerosis.- 1977.- № 27.- p. 1−13.
- Stucki G., Schonbachler J., Bruhlmann P., Mariacher S. Does a muscle strength index provide complementary information to traditional disease activity variables in patients with rheumatoid arthritis // J Rheumatol.- 1994.- № 21.- p. 22 005.
- Swaak A. Anemia of chronic disease in patients with rheumatoid arthritis: aspects of prevalence, outcome, diagnosis and the effects of treatment on disease activity // J Rheum.- 2006.- № 33(8).- p. 1467−8.
- Szmitko P.E., Wang C.H., Weisel R.D., et al. New markers of inflammation and endothelial cell activation // part II Circulation.- 2003.-№ 108.- p. 2041−8.
- Takahashi S., Moriwaki Y., Yamamoto T. et al Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism // Ann. Rheum Dis.- 2003.- № 62.- p. 572−575.
- Takahashi S., Yamamoto Т., Moriwaki Y. et al. Impaired lipoprotein metabolism in patients with primary gout Influence of alcohol intake and body weight // Br. J. Rheumatol.- 1994.- № 33.- p. 731−734.
- Takahashi S., Yamamoto Т., Moriwaki Y. et al. Increased concentrations of serum Lp (a) lipoprotein patients with primary gout // Ann. Rheum. Dis.- 1995.- № 54.-p. 90−93.
- Tappy L., Bovet P., Jequier T. et al. Relationship of fasting serum insulin concentrations with blood pressure in a representative sample of the adult population of the Seychelles // Int. J. Obesity.- 1991.- № 15.- p. 669 675.
- TeChao Fang, WannChu Huang. Angiotensin receptor blockade blunts hyperinsulinemiaindused hypertension in rats // Hypertension.- 1998.- № 32.- p. 235−242.
- Tedde R., Sechi L.A., Marigliano A. et al. Antihypertensive effect of insulin reduction in diabetichypertensive patients // Am.J. Hypertens.- 1989.- № 2.- p. 163−170.
- Terkeltaub R.A. Clinical practice. Gout // N Engl J Med.- 2003.- № 349.-p. 1647−55.
- Terkeltaub R.A. Pathogenesis and treatment of crystal-induced inflammation. In: Koopman WJ, editor. Arthritis and allied conditions.- 14th ed. Philadelphia: Lippincott Williams & Wilkins, 2001. p. 2329−2347.
- Toss H., Lindahl В., Siegbahn A. et al. for the FRISC Study Group. Prognostic influence of fibrinogen and C-reactive protein levels in unstable coronary artery disease // Circulation.- 1997.- № 96.- p. 4204−10.
- Tracy R.P. Inflammation markers and coronary heart disease // CurrOpin Lipidol.- 1999.- № 10.- p. 435−441.
- Troen B.R. The biology of aging // Mt Sinai J Med.- 2003.- № 70.- p. 3−22.
- Tsunoda K., Abe K., Hagino Т., Omata K., Misawa S., Imai Y., et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension // Am J hypertens.- 1993.- № 6.- p. 28−32.
- Turner R.E., Frank M.J., Van Ausdal D., et al. Some aspects of the epidemiology of gout // Arch Intern Med.- I960.- № 106.- p. 400−406.
- Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion // Nephron.- 1991.-№ 59.-p. 364−368.
- US Renal Data System. USRDS 1999 annual data report. Bethesda (MD): National Institute of Health (US), National Institute of diabetes and Digestive and Kidney Diseases.- 1999.
- Vague J. The degree of masculine differentiation of obesities, a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease // Am J Clin Nulr.- 1956.- № 4 (2).- p. 20−34.
- Van der Heijde D., Landewe R. Selection of a methods for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT // J Rheum.- 2005.-№ 32(10).-p. 2048−9.
- Vandenberg M.K., Moxley G., Breitbach S.A., Roberts W.N. Gout attacks in chronic alcoholics occur at lower serum urate levels than in nonalcoholics // J Rheum.- 1994.- № 21(4).- p. 700−704.
- Vasan R.S., Sullivan L.M., Wilson P.W., et al. Relative importance of borderline and elevated levels of coronaiy heart disease risk factors // Ann Intern Med.- 2005.-№ 142.-p.393.
- Vazguez-Mellado J., Garsia C.G., Vazguez S.G. et al. Metabolic syndrome and ischemic heart disease in gout // J. Clin. Rheumatol.- 2004.- № 10 (3).-p. 105−109.
- Vozarova В., Weyer С., Hanson К., Tataranni P.A., Bogardus С., Pratley R.E. Circulating interleulcin-6 in relation to adiposity, insulin action, and insulin secretion // Obes Res.- 2001.- № 9.- p. 414−417.
- Vuorine-Marklcola H., Yki-Jarvinen H. Hyperuricemia and insulin resistance // J Clin Endocrinol Metab.- 1994.- № 78.- p. 25−29.
- Wakabayashi I. Age-related change in relationship between body-mass index, serum sialic acid, and atherogenic risk factors // J Atheroscler Thromb.- 1998.-№ 5.-p. 60−65.
- Wallace K.L., Riedel A.A., Joseph-Ridge N., Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adult in a managed care population // J.Rheumatol.- 2004.-№ 31.- p. 1582−7.
- Wallace S.L., Robinson H., Masi A.T. et al. Preliminary criteria for the classification of the acute arthritis of gout // Arthritis Rheum.- 1977.- № 20.- p. 895 900.
- Walton C., Lees В., Crook D. et al. Relationships between insulin metabolism, serum lipid profile, body fat distribution and blood pressure in healthy men//Atherosclerosis.- 1995,-№ 118.-p. 35−43.
- Wasada T. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics // Diabetologia.- 2000.- № 43.- p. 814 820.
- Watson R.L., Langford H.G. Weight, urinary electrolytes and blood pressure. Results of several community based studies // J.Chron.Dis.- 1982.- № 35 (12).-p. 909−918.
- Weaver J.U., Koppdman P.G., Hitman G.A. Central obesity and hyperinsulinemia in women are associated with polymorphism in the 5″ flanking region of the human insulin gene // Eur J Clin Investig.- 1992.- № 22(4).- p. 265−270.
- Wehr H. Effect of ethyl alcohol on the metabolism of lipids and lipoproteins // Przegl Lek.- 1987.- № 44(6).- p. 510−512.
- Weinberger A., Schumacher H.R., Agudelo C.A. Urate crystal in asymptomatic metatarsophalangeal joints // Ann Intern Med.- 1979.-№ 91.- p. 56−57.
- Weinman E.J., Eknoyan G., Suki W.N. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid // J Clin Invest.- 1975.-№ 55.- p. 283.
- Weiss Т.Е., Segaloff A. Gouty Arthritis and Gout. Springfield, III, Thomas, 1959, p. 7.
- Welborn T.A., Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations // Diabetes Care.- 1979.-№ 2.- p. 154−160.
- Whitehead T.P., Jungner I., Robinson D., et al. Serum urate, serum glucose and diabetes // Ann Clin Biochem.- 1992.-№ 29.- p. 159−161.
- Wick M., Peloschek P., Bogl K., et al. The «X-Ray RheumaCoach» software: a novel tool for enchancing the efficacy and accelerating radiological quantification in rheumatoid arthritis // Ann Rheum Dis.- 2003.- № 62.- p. 579−582.
- Wiernsperger N.F., Bailey C.J. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs // 1999.- № 58 (Suppl 1).- p. 31−9 (discussion 75−82).
- Wilson P.W., D’Agostino R.B., Levy D. Prediction of coronary heart disease using risk factor categories // Circulation.- 1998.-№ 97.- p. 1837−47.
- Wilson P.W. Established risk factors and coronary artery disease: The Framingham Study // Am J Hypertens.- 1994.- № 7.- p. 7.
- World Health Organization (WHO). Obesity: prevention and management of the global epidemic. Report of the WHO Consultation // World Health Organ Tech Rep Ser.- 2000.- № 894 (i-xii).- p. 1−253.
- World Health Organization (WHO). Prevention and management of the global epidemic of obesity. Report of the WHO Consultation on Obesity — Geneva: WHO, 1997. h
- Wyngaarden J.B., Kelley W.N. Gout and hyperuricemia. New York, 1976,512 р.
- Yamashita S, Nakamura T, Shimomura I et al. Insulin resistance and body fat distribution // Diabetes Care.- 1996.-№ 19.- p. 287−291.
- Yu T. Berger L., Dorph D.J., Smith H. Renal function in gout. V. Factors influencing the renal hemodinamics // Am J Med.- 1979.-№ 67.- p. 766−771.
- Yu Т., Berger L. Renal disease in primary gout: a study of 253 gout patients with proteinuria // Semin Arthritis Rheum.- 1975.- № 4.- p. 293−305.
- Yu T.F. Diversity of clinical features in gouty arthritis // Semin Arth Rheum.- 1984.-№ 13.- p. 360−368.
- Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study // Lancet.- 2004.-№ 364, — p. 937.
- Zang S.L., Chen X., Hsieh T.J., et al. Hyperglycemia induces insulin resistance on angiotensinogen gene expression in diabetic rat kidney proximal tubular cells // J. Endocrinol.- 2002.-№ 172 (2).- p. 333−344.